While the MYC molecule itself is challenging as a pharmacological target, the discovery that BET inhibitors result in the effective reduction of MYC transcript and protein levels66 has highlighted the possibility of utilizing epigenetic pharmacology in cancer therapy to circumvent molecules unamenable to direct targeting. Here, MYC is linked to cancer.